Free Newsletter
Catalyst offers more efficient drug production method
A team of professors at the Boston College Chemistry Department have developed a small molecule catalyst they say can significantly streamline the production of therapeutics and chemicals. The essence of their work focused on the mirror-image molecules that are present in chemical compounds. One of those two hands, or enantiomers, can be harmful. The team--led by Amir Hoveyda and Marc Snapper--developed a "silylation catalyst" so that only one hand is formed, reducing the number of steps in the process from five to one.
"This is an elegant solution to a very important, practical problem, with the potential to result in more efficient, more environmentally friendly, and less expensive processes for manufacturing drugs," said John M. Schwab, a chemist at the National Institute of General Medical Science, which supported the work.
- read this report on the catalyst from the Royal Society of Chemistry
More stories about molecules
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
